Driving Forces Behind the Cytokine Release Syndrome Treatment Market in 2025: Spotlight on Increasing Prevalence Of Cancer Treatments Drives Growth In Cytokine Release Syndrome Treatment Market Driver
The cytokine release syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune disorders, increasing incidence of cancer therapies, increasing availability of targeted therapies, rising investment in biotechnology and life sciences, rising use of monoclonal antibodies. Major trends in the forecast period include implementation of biomarker based therapies, development of next generation IL-6 inhibitors, advancements in CAR-T cell therapy, adoption of biosimilars, advancements in monoclonal antibody therapies.
Get Your Free Sample of The Global Cytokine Release Syndrome Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
What are the key drivers behind the rapid expansion of the cytokine release syndrome treatment market?
The increasing prevalence of cancer treatments is expected to propel the growth of the cytokine release syndrome (CRS) treatment market going forward. The growing prevalence of cancer treatments is driven by the rising global incidence of cancer and advancements in diagnostic technologies, which enable earlier detection and a broader range of treatment options. Additionally, improved survival rates and expanded access to healthcare contribute to the growing demand for these therapies. CRS treatment involves supportive care, anti-cytokine therapies, and ongoing monitoring to manage symptoms and mitigate the inflammatory response caused by cancer treatments. For instance, in January 2023, according to the National Health Service (NHS), a UK-based healthcare system, over 320,000 people received cancer treatment from November 2021 to October 2022, marking the highest number ever recorded and an increase of over 8,000. Therefore, the increasing prevalence of cancer treatments is driving the cytokine release syndrome treatment market.
What is the segmentation for the cytokine release syndrome treatment market?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-treatment-global-market-report
Who are the most influential companies in the cytokine release syndrome treatment market?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
What are the most influential trends expected to drive the cytokine release syndrome treatment market forward?
Major companies operating in the cytokine release syndrome treatment market are advancing drug delivery technologies such as intravenous infusion to improve treatment precision, reduce side effects, and enhance patient outcomes. Intravenous infusion in the treatment of cytokine release syndrome allows fast and accurate administration of drugs into the bloodstream, ensuring prompt therapeutic action. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received regulatory approval for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody from the Ministry of Health, Labor, and Welfare, a Japan-based government authority, to treat cytokine release syndrome (CRS) induced by various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) is an additional indication in treating cytokine release syndrome (CRS) caused by cancer therapy. With this new indication, Actemra can now be used as an anti-cytokine therapy for CRS resulting from cancer treatments beyond tumor-specific T-cell infusion therapy.
What are the major regional insights for the cytokine release syndrome treatment market, and which region holds the top position?
North America was the largest region in the cytokine release syndrome treatment market in 2024. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cytokine Release Syndrome Treatment Market Report 2025 Offer?
The cytokine release syndrome treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cytokine release syndrome (CRS) treatment refers to medical interventions designed to manage and mitigate the severe inflammatory response triggered by cytokine release, associated with certain therapies such as CAR-T cell treatments. It helps control symptoms, reduce inflammation, and improve patient outcomes during intense cytokine reactions.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20542
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment